Resources
- BNET Author Biography
- Trista Morrison is a staff writer at BioWorld Today, a daily newspaper that
- more about Trista Morrison »
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- The Business Conundrums of Trying to Prevent Cancer
- An article in last week's New York Times said drug companies are not particularly interested in preventing cancer -- because patients aren't particularly interested in buying drugs for cancer prevention. by Trista Morrison
- Blog posts 2009-11-18
- The Scoop on MannKind's Afresa Partnership Delay
- MannKind’s president and chief operating officer, Hakan Edstrom, explains why the company's partnership for inhaled insulin product Afresa has been delayed. by Trista Morrison
- Blog posts 2009-10-11
- Are You Sure You Want Off-Label Drug Promotion Protected Under Freedom of Speech?
- On what planet is Allergan's lawsuit, which claims the FDA's off-label drug promotion ban violates the First Amendment right to free speech, a good idea? It doesn't appear to serve the greater good for the public or even for the drug industry. by Trista Morrison
- Blog posts 2009-10-07
- Talecris IPO Gives Cerberus Much-Needed Happy Ending
- The $950 million initial public offering priced by Talecris Biotherapeutics last week was good for a lot of people -- perhaps none more than private equity firm Cerberus Partners, which was desperately in need of a happy ending. by Trista Morrison
- Blog posts 2009-10-05
- Chelsea and Catalyst Roll the Dice on Re-Analyses, Investors Take the Bet
- Chelsea Therapeutics and Catalyst Pharmaceutical Partners both enjoyed nice stock bumps last week thanks to re-analyses of failed clinical trials, even though such analyses often prove to be nothing but trouble for biotechs. by Trista Morrison
- Blog posts 2009-10-04
- Dirty Politicians Pressured the FDA to Approve Something Unsafe? Say It Ain't So.
- The FDA is investigating one of its past approval decisions, publicly questioning for the first time whether or not political pressure unduly influenced an outcome. Note this is the first time they're questioning it -- not necessarily the first time it has happened. by Trista Morrison
- Blog posts 2009-09-30
- War Stories II: Sunesis Hunkers Down and Gets Creative to Stay Alive
- In another war story from the BioPharm America conference front lines, Sunesis CEO Dan Swisher tells how his company, on the brink of running out of cash in January, hunkered down and got creative with its investors to close a PIPE. by Trista Morrison
- Blog posts 2009-09-28
- War Stories I: Turnaround Takes MDRNA from Two Weeks of Cash to Seven Deals
- At the recent BioPharm America conference in San Francisco, biotech CEOs and investors swapped war stories - including this one about how MDRNA made it back from the brink. by Trista Morrison
- Blog posts 2009-09-27
- Who's Afraid of Big, Bad Cardiovascular? Apparently Not Biotech...
- Cardiovascular disease brings to mind huge, expensive clinical trials and huge, expensive primary care sales forces…but not necessarily huge, expensive drug prices. With the basics of cholesterol management met, some big pharmas are turning away from the field, but enterprising biotechs are stepping in. by Trista Morrison
- Blog posts 2009-09-24
- Playing Devil's Advocate on the Talecris IPO: A Banker Provides the Contrarian View
- Earlier this week, I argued that you’d have to be a fool to buy into the Talecris Biotherapeutics initial public offering. Now a banker presents the other side of the story. by Trista Morrison
- Blog posts 2009-09-23
- Biotech Fundraising Options for Those With No Options
- Yes, the financing climate appears to be thawing, and for those with good data, it’s been positively hot. But there are still plenty of biotechs being forced to get creative with their fundraising efforts. by Trista Morrison
- Blog posts 2009-09-21
- What Fool Will Buy the Talecris IPO? Oh Wait, That'll Be Me.
- It’s hard to imagine why anyone would want to buy a piece of Talecris Biotherapeutics’ proposed $850 million initial public offering. VentureBeat said it best when Talecris tried to go public two years ago: So what we have is a profitable but relatively slow-growing biotech with...
- Blog posts 2009-09-20
- Pity Party's Over: Survey Says Scientist Salaries on the Rise
- Despite the fact that companies across the board are freezing salaries, skipping bonuses and reminding employees they should feel lucky just to have a job, scientists are still raking in the big bucks according to The Scientist's annual salary survey. by Trista Morrison
- Blog posts 2009-09-14
- Why Vivus's Qnexa Might Avoid the Obesity Drug Graveyard
- Vivus’s better-than-expected Phase III data with obesity drug Qnexa started the goldmine versus graveyard debate once again. In one corner: the folks who think obesity is the last frontier. In the other corner: the folks like BNET’s own Jim Edwards, who argues that obesity drugs are doomed to failure. by...
- Blog posts 2009-09-13
- Former CellCyte Execs Sued by SEC for Role in Pump and Dump Stock Scheme
- In case you were wondering why counsel always cuts the hype out of your press releases…CellCyte Genetics and its former top execs got slapped with an SEC lawsuit for their role in a hype-driven pump-and-dump stock scheme. by Trista Morrison
- Blog posts 2009-09-10
- Drama Runs in Facet Biotech's Family -- Just Ask Parent PDL BioPharma
- Biotech is no stranger to contentious negotiations with potential acquirers, or activist investors demanding liquidation, or product failures, or reorganizations, or patent fights. But PDL BioPharma has to be wondering: why does everything happen to us? by Trista Morrison
- Blog posts 2009-09-08
- Well Isn't That Special: Overall Survival Still Oncology Gold Standard
- There’s a world of difference between thinking your kid is the smartest in class and selling the principal on the idea, as cancer drug makers are learning when trying to sell the FDA on progression-free survival as a primary endpoint. by Trista Morrison
- Blog posts 2009-10-12
- Depomed Unfairly Slammed for Serada Phase III Results
- Under-the-radar drug delivery firm Depomed doesn't deserve the heat it's been taking on mixed results from two Phase III trials of hot flash drug Serada. by Trista Morrison
- Blog posts 2009-10-13
- BioPure Exec Sentenced to Three Years for Faking Cancer to Avoid SEC Probe
- Howard Richman better hope there's no such thing as karma. The former BioPure vice president was sentenced last month to three years in prison for faking cancer to avoid an SEC investigation. by Trista Morrison
- Blog posts 2009-11-16
- Will Plavix Competitor Cangrelor Be a Prince Rather than a Frog for The Medicines Co.?
- The Medicines Co., which six months ago stopped two likely-to-fail Phase III trials of antiplatelet drug cangrelor, is out to prove its frog of a drug may be a prince after all. by Trista Morrison
- Blog posts 2009-11-15
- << Previous
- page 1 of 4
- Next >>
Refining Tags
- Biotechnology (27 results)
- Finance (15 results)
- Government (11 results)
- Investment (11 results)
- Federal Government (9 results)
- IPO (6 results)
- Financial Planning (6 results)
- Financial Services (6 results)
- Financial Accounting (5 results)
- Human Resources (5 results)
- Marketing (4 results)
- Cancer (4 results)
- Healthcare (4 results)
- Medicines Co. (3 results)
- FDA (3 results)
- Investor (3 results)
- Pharmaceutical Company (3 results)
- Amgen Inc. (3 results)
- Management (3 results)
- Workforce Management (3 results)
- Genentech Inc. (3 results)
